179 related articles for article (PubMed ID: 23264893)
1. Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin's lymphoma.
Kato J; O'Donnell RT; Abuhay M; Tuscano JM
Oncoimmunology; 2012 Dec; 1(9):1469-1475. PubMed ID: 23264893
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.
Kato J; Satake N; O'Donnell RT; Abuhay M; Lewis C; Tuscano JM
Leuk Res; 2013 Jan; 37(1):83-8. PubMed ID: 23040543
[TBL] [Abstract][Full Text] [Related]
3. The HB22.7-vcMMAE antibody-drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity.
Abuhay M; Kato J; Tuscano E; Barisone GA; Sidhu RS; O'Donnell RT; Tuscano JM
Cancer Immunol Immunother; 2016 Oct; 65(10):1169-75. PubMed ID: 27506529
[TBL] [Abstract][Full Text] [Related]
4. Treatment of non-Hodgkin's lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy.
O'Donnell RT; Pearson D; McKnight HC; Ma YP; Tuscano JM
Cancer Immunol Immunother; 2009 Oct; 58(10):1715-22. PubMed ID: 19294384
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma.
Polson AG; Williams M; Gray AM; Fuji RN; Poon KA; McBride J; Raab H; Januario T; Go M; Lau J; Yu SF; Du C; Fuh F; Tan C; Wu Y; Liang WC; Prabhu S; Stephan JP; Hongo JA; Dere RC; Deng R; Cullen M; de Tute R; Bennett F; Rawstron A; Jack A; Ebens A
Leukemia; 2010 Sep; 24(9):1566-73. PubMed ID: 20596033
[TBL] [Abstract][Full Text] [Related]
6. The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner.
Martin SM; Churchill E; McKnight H; Mahaffey CM; Ma Y; O'Donnell RT; Tuscano JM
J Hematol Oncol; 2011 Dec; 4():49. PubMed ID: 22128838
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.
Kong Y; Barisone GA; Abuhay M; O'Donnell RT; Buksh Z; Yousefian F; Tuscano JM
Leuk Res; 2014 Nov; 38(11):1320-6. PubMed ID: 25241275
[TBL] [Abstract][Full Text] [Related]
8. Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts.
O'Donnell RT; Ma Y; McKnight HC; Pearson D; Tuscano JM
Cancer Immunol Immunother; 2009 Dec; 58(12):2051-8. PubMed ID: 19437017
[TBL] [Abstract][Full Text] [Related]
9. An Anti-CD22-
Yu SF; Lee DW; Zheng B; Del Rosario G; Leipold D; Booler H; Zhong F; Carrasco-Triguero M; Hong K; Yan P; Rowntree RK; Schutten MM; Pillow T; Sadowsky JD; Dragovich PS; Polson AG
Mol Cancer Ther; 2021 Feb; 20(2):340-346. PubMed ID: 33273056
[TBL] [Abstract][Full Text] [Related]
10. A Novel Anti-CD22 Anthracycline-Based Antibody-Drug Conjugate (ADC) That Overcomes Resistance to Auristatin-Based ADCs.
Yu SF; Zheng B; Go M; Lau J; Spencer S; Raab H; Soriano R; Jhunjhunwala S; Cohen R; Caruso M; Polakis P; Flygare J; Polson AG
Clin Cancer Res; 2015 Jul; 21(14):3298-306. PubMed ID: 25840969
[TBL] [Abstract][Full Text] [Related]
11. Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.
Tuscano JM; Martin SM; Ma Y; Zamboni W; O'Donnell RT
Clin Cancer Res; 2010 May; 16(10):2760-8. PubMed ID: 20460479
[TBL] [Abstract][Full Text] [Related]
12. Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.
Tuscano JM; O'Donnell RT; Miers LA; Kroger LA; Kukis DL; Lamborn KR; Tedder TF; DeNardo GL
Blood; 2003 May; 101(9):3641-7. PubMed ID: 12511412
[TBL] [Abstract][Full Text] [Related]
13. Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Mehta A; Forero-Torres A
Curr Oncol Rep; 2015 Sep; 17(9):41. PubMed ID: 26194424
[TBL] [Abstract][Full Text] [Related]
14. Anti-CD22 and anti-CD79b antibody-drug conjugates preferentially target proliferating B cells.
Fuh FK; Looney C; Li D; Poon KA; Dere RC; Danilenko DM; McBride J; Reed C; Chung S; Zheng B; Mathews WR; Polson A; Prabhu S; Williams M
Br J Pharmacol; 2017 Apr; 174(8):628-640. PubMed ID: 28009435
[TBL] [Abstract][Full Text] [Related]
15. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
Aujla A; Aujla R; Liu D
Biomark Res; 2019; 7():9. PubMed ID: 31011424
[TBL] [Abstract][Full Text] [Related]
16. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma.
Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM
Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696
[TBL] [Abstract][Full Text] [Related]
17. Brentuximab vedotin in Hodgkin's lymphoma.
Pro B; Perini GF
Expert Opin Biol Ther; 2012 Oct; 12(10):1415-21. PubMed ID: 22937794
[TBL] [Abstract][Full Text] [Related]
18. Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD).
O'Donnell RT; Martin SM; Ma Y; Zamboni WC; Tuscano JM
Invest New Drugs; 2010 Jun; 28(3):260-7. PubMed ID: 19306119
[TBL] [Abstract][Full Text] [Related]
19. Targeting CD22 in B-cell malignancies: current status and clinical outlook.
Sullivan-Chang L; O'Donnell RT; Tuscano JM
BioDrugs; 2013 Aug; 27(4):293-304. PubMed ID: 23696252
[TBL] [Abstract][Full Text] [Related]
20. Antibody-Drug Conjugates for Cancer Treatment.
Lambert JM; Berkenblit A
Annu Rev Med; 2018 Jan; 69():191-207. PubMed ID: 29414262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
